In an unusual move, Celgene has backed out of a $55 million settlement with patients and payers over allegations it illegally blocked competition to multiple myeloma meds Thalomid and Revlimid. With the decision, the company will go back to fighting claims from thousands of patients and payers, who allege billions in damages.
Featured News
Paul Weiss Bolsters M&A Practice With Senior Partner Hire From Goodwin
Nov 16, 2026 by
CPI
Samsung, SK Hynix and Micron Lose Bid to Dismiss US DRAM Antitrust Suit
Nov 16, 2026 by
CPI
US Attorney Warns Warren Over Plans to Scrutinize Trump-Linked Deals
Nov 16, 2026 by
CPI
EU Clears UniCredit’s Commerzbank Acquisition Without Conditions
Nov 16, 2026 by
CPI
Europe’s Smaller Soccer Clubs Take on UEFA in Antitrust Fight
Nov 16, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Data Portability
Nov 12, 2026 by
CPI
Mandating Access to a Dominant Platform’s Inferred Data: A Two Scenario Diagnosis
Nov 12, 2026 by
Sean Ennis
Data Portability Between Individual Control and Data Sharing at Scale
Nov 12, 2026 by
Jasper van den Boom & Inge Graef
Information Also Wants to Be Expensive: Data Portability and the Open-Systems Creed
Nov 12, 2026 by
Justin (Gus) Hurwitz
Data Portability’s Cybersecurity Paradox: When Protecting Consumer Data Restricts Competition
Nov 12, 2026 by
Sasha Hondagneu-Messner